MIF and breast cancer: Such finding might signify that MIF is a probable marker for aggressive BC conditions characterized by poor prognosis, recurrence, metastasis, and lack of specific therapeutic targets [37], suggesting a potential use of anti-MIF agents, such as Imalumab which is still processed in clinical trials and showing promising antitumor activity in patients with advanced solid tumors.